PROBES

Selecting the right therapy using molecular imaging

Up to ~70% of cancer patients will not see any response from their treatment. They take on significant risk with no benefit, adverse side effects, and a large loss of time and money.

Now imagine a future where physicians use whole body diagnostics to quickly select the right therapy.

A new class of molecular imaging (PET) agents may provide a safe, non-invasive technique to image the biology of disease.

18F-FAC Image Gallery

Clinical Bio-Distribution, Healthy Subject

Clinical Non-Hodgkin Lymphoma

Preclinical Autoimmune Mouse Model

Preclinical dCK KO vs. WT Mouse

Preclinical Tumor Model

Movie

How Can
18F-FAC Help You?

Through discovery, invention, and product development, Sofie is committed to doing its part to change the world of molecular imaging by creating an accessible and economic route to the widespread use of PET.

We are dedicated to the continual development of PET probes to assist basic and clinical scientists as they study the biological transformation of normal cellular functions into a disease state. It’s our mission to help guide the discovery and development processes leading to the widespread use of molecular therapeutics. Developing semi-automated chemistry modules for onsite synthesis of 18F-FAC, and other probes, is an example of this commitment.

18F-FAC Applications

ONCOLOGY

18F-FAC PET may be used for:

  • Treatment Stratification – Predicting Patient Response to Nucleoside Pro-Drugs
  • Determining dose schedules with Nucleoside Pro-Drugs
IMMUNOLOGY

18F-FAC PET may be used for:

  • Measuring Immune Response in Drug Discovery and Development
  • Investigating and predicting efficacy of Immunotherapies
  • Monitoring Transplant Rejection and Graft-Versus-Host-Disease
  • Diagnosis and Staging of Auto-Immune Disorders
Back to top ↑